FindTrial
Sign In

Study of role of certain blood tests in predicting the severity of ovarian cancer

Study of association of C reactive protein and albumin ratio with clinicopathological factors in cases of ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/034317
Enrollment
100
Registered
2021-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

None listed

Sponsors

TATA main hospital
Lead Sponsor
TATA main hospital
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All new cases of ovarian malignancy

Exclusion criteria

Exclusion criteria: Patients with borderline ovarian tumors 2.clinical evidence of infection or other inflammatory conditions 3. Secondary malignancy or multiple primary malignancies

Design outcomes

Primary

MeasureTime frame
association between CRP/albumin ratio and clinicopathological factors- Age, tumor stage and grade, histological features, ascites, lymph node involvement, tumor markersTimepoint: October 2022—

Secondary

MeasureTime frame
Comparison between predictive ability of CRP/albumin ratio and CA-125Timepoint: October 2022—

Countries

India

Contacts

Public ContactDr Vinita singh

TATA main hospital

drvinitasingh@tatasteel.com7763807743

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026